Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Dexcom Inc | 1,260 |
| 2 | Merck Sharp & Dohme LLC | 1,210 |
| 3 | Pfizer Inc | 837 |
| 4 | Glaxo Group Ltd | 828 |
| 5 | F Hoffmann La Roche AG | 785 |
| 6 | Organon Pharma UK Ltd | 649 |
| 7 | Pfizer Corp SRL | 639 |
| 8 | Janssen Pharmaceutica NV | 627 |
| 9 | NTG Nordic Transport Group AS | 586 |
| 10 | Pfizer Products Inc | 564 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 36,703 |
| 2 | A61K | Medicinal preparations | 32,468 |
| 3 | C07D | Heterocyclic compounds | 20,710 |
| 4 | G01N | Investigating / analysing materials | 8,564 |
| 5 | C07K | Peptides | 4,639 |
| 6 | A61B | 4,284 | |
| 7 | Y02A | Climate change adaptation | 3,492 |
| 8 | C12N | Microorganisms, enzymes | 3,474 |
| 9 | C07C | Acyclic and carbocyclic compounds | 3,246 |
| 10 | A61M | Devices for introducing media into the body | 2,555 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Sensors for sugars and other metal binding analytes | 2000 | California Institute of Technology | 466 |
| Combination of sugars with animo acids and other drugs | 1995 | Naito, Albert | 127 |
| SUSTAINED LOCAL ANESTHETIC COMPOSITION CONTAINING PREFERABLY A SUGAR ESTER SUCH AS SAIB | 2006 | Durect Corp | 23 |
| SWEETNESS ENHANCED SUGARS AND SUGAR LIKE PRODUCTS | 2012 | ABBA PHARMA LIMITED | 20 |
| Message processing method and device based on Snort rule set | 2011 | DAWNING INFORMATION INDUSTRY (BEIJING) CO., LTD. | 12 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Neurotransmitter Receptor Influence on Behavior | 243 |
| 2 | Forensic Toxicology and Drug Analysis | 114 |
| 3 | Prenatal Substance Exposure Effects | 65 |
| 4 | Substance Abuse Treatment and Outcomes | 64 |
| 5 | Neuroscience and Neuropharmacology Research | 33 |
| 6 | Opioid Use Disorder Treatment | 24 |
| 7 | Cannabis and Cannabinoid Research | 20 |
| 8 | HIV, Drug Use, Sexual Risk | 17 |
| 9 | Attention Deficit Hyperactivity Disorder | 15 |
| 10 | HIV Research and Treatment | 11 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Eric J. Nestler | Icahn School of Medicine at Mount Sinai | 146 |
| 2 | Peter W. Kalivas | Medical University of South Carolina | 141 |
| 3 | Thomas R. Kosten | Yale University | 139 |
| 4 | Nora D. Volkow | Brookhaven National Laboratory | 130 |
| 5 | Amy Hauck Newman | National Institute on Drug Abuse | 111 |
| 6 | George F. Koob | Scripps Research Institute | 98 |
| 7 | Jonathan L. Katz | National Institute on Drug Abuse | 96 |
| 8 | F. Ivy Carroll | RTI International | 95 |
| 9 | Mary Jeanne Kreek | Rockefeller University | 79 |
| 10 | Michael A. Nader | Wake Forest University | 77 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Guía de práctica clínica para el tratamiento de los tumores intracraneales | 2009 | 5280 | Neuroblastoma Research and Treatments |
| The 2007 WHO Classification of Tumours of the Central Nervous System | 2007 | 4567 | Glioma Diagnosis and Treatment |
| The fifth edition of the addiction severity index | 1992 | 4262 | Substance Abuse Treatment and Outcomes |
| The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence | 1985 | 2523 | Schizophrenia research and treatment |
| Natural Antibiotic Resistance and Contamination by Antibiotic Resistance Determinants: The Two Ages in the Evolution of Resistance to Antimicrobials | 2012 | 2107 | Antibiotic Resistance in Bacteria |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular formula and weight of this compound?
Which research topics are most frequently associated with publications on this compound?
Who are the leading authors publishing research on this compound?
What patent classification codes dominate the patent landscape for this compound?
How has research publication activity trended in recent years?